![Angharad Watson](https://profiles-cardiff.imgix.net/attachments/1551?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Angharad Watson
(she/her)
Centre Manager for the Digital Transformation Innovation Institute
Overview
Dr Angharad Watson is the Centre Manager for the university's strategic flagship Digital Transformation Innovation Institute. Her role is to support the advancement of interdisciplinary research focused on digital transformation, with a strong focus on impact and innovation. As part of this, she supports a positive research culture within the university, leading the institute's early career researcher development programme and sitting on the board of EMPOWER, an internal Cardiff University network of aspiring principal investigators who identify as women. She respresents an active virtual institute with research interests spanning all three of the university colleges, in areas as diverse as cybersecurity, healthcare, transport, and fintech, among others. She manages a number of relationships with key industry partners, and acts to bring together Cardiff researchers with local and international collaborators in other HEIs, businesses, public sector organisations, and other interested groups. She welcomes contact from any parties interested in working with the university on digital transformation research and innovation projects.
Publication
2024
- Hatch, S., Edwards, K., Watson, A. and Matthews, J. 2024. The Life Sciences Challenge: delivering an all-Wales bilingual inter-school competition for over 10 years and throughout a global pandemic. Research for All 8(1) (10.14324/rfa.08.1.10)
2019
- Watson, H. A. et al. 2019. L-selectin enhanced T cells improve the efficacy of cancer immunotherapy. Frontiers in Immunology 10, article number: 1321. (10.3389/fimmu.2019.01321)
2016
- Ager, E., Watson, H. A., Wehenkel, S. C. and Mohammed, R. N. 2016. Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells. Biochemical Society Transactions 44(2), pp. 377-385. (10.1042/BST20150254)
- Watson, H. A., Wehenkel, S., Matthews, J. and Ager, E. 2016. SHP-1: the next checkpoint target for cancer immunotherapy?. Biochemical Society Transactions 44(2), pp. 356-362. (10.1042/BST20150251)
- Mohammed, R. N., Watson, H. A., Vigar, M., Ohme, J., Thomson, A., Humphreys, I. R. and Ager, A. 2016. L-selectin is essential for delivery of activated CD8+ T cells to virus-infected organs for protective immunity. Cell Reports 14(4), pp. 760-771. (10.1016/j.celrep.2015.12.090)
2014
- Spary, L. K. et al. 2014. Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation. The Journal of Immunology 192(7), pp. 3101-3110. (10.4049/jimmunol.1302736)
Erthyglau
- Hatch, S., Edwards, K., Watson, A. and Matthews, J. 2024. The Life Sciences Challenge: delivering an all-Wales bilingual inter-school competition for over 10 years and throughout a global pandemic. Research for All 8(1) (10.14324/rfa.08.1.10)
- Watson, H. A. et al. 2019. L-selectin enhanced T cells improve the efficacy of cancer immunotherapy. Frontiers in Immunology 10, article number: 1321. (10.3389/fimmu.2019.01321)
- Ager, E., Watson, H. A., Wehenkel, S. C. and Mohammed, R. N. 2016. Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells. Biochemical Society Transactions 44(2), pp. 377-385. (10.1042/BST20150254)
- Watson, H. A., Wehenkel, S., Matthews, J. and Ager, E. 2016. SHP-1: the next checkpoint target for cancer immunotherapy?. Biochemical Society Transactions 44(2), pp. 356-362. (10.1042/BST20150251)
- Mohammed, R. N., Watson, H. A., Vigar, M., Ohme, J., Thomson, A., Humphreys, I. R. and Ager, A. 2016. L-selectin is essential for delivery of activated CD8+ T cells to virus-infected organs for protective immunity. Cell Reports 14(4), pp. 760-771. (10.1016/j.celrep.2015.12.090)
- Spary, L. K. et al. 2014. Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation. The Journal of Immunology 192(7), pp. 3101-3110. (10.4049/jimmunol.1302736)
Biography
Dr Angharad Watson has an academic background in cell biology and advanced therapies, having held research posts at the University of Manchester, Cardiff University, and at biotech companies. She holds an undergraduate Master's degree in Molecular and Cellular Biochemistry from Oxford University, and a PhD in cell biology from the University of Manchester. She was research active from 2010 to 2018, mostly based at Cardiff University's School of Medicine. In 2019 she joined Cardiff University's Strategic Planning and Governance team as a REF Impact Officer, supporting the delivery of Impact Case Studies for REF 2021. Following this, she took on the role of Life Science Research Network Wales Manager. The Network was a European-funded pan-Wales initiative bringing together over 300 life science researchers to address translational research challenges with a strong emphasis on drug discovery. In 2021 she was seconded to the Wellcome Trust as a Portfolio Manager in Immunology, supporting the transition to from their legacy funding schemes to their new Discovery Research schemes. Following this, she took over management of Cardiff University's Wellcome Institutional Translation Partnership Award, supporting Cardiff researchers to progress their research along the translational pathway. This award closed in 2022, at which point she was appointed to manage the University's new Digital Transformation Innovation Institute, which was officially launched in March 2023.
Committees and reviewing
2024 UKRI Cross Research Council Responsive Mode Interdisciplinary Assessment College
Contact Details
+44 29208 74478
sbarc|spark, Room 03.14, Maindy Road, Cathays, Cardiff, CF24 4HQ
